Pfizer's ELREXFIO Succeeds In Phase 3 Trial For Multiple Myeloma

Pfizer (PFE) reported positive Phase 3 trial results for ELREXFIO in relapsed or refractory multiple myeloma, meeting its primary endpoint of progression-free survival. The study showed significant risk reduction compared to existing treatments. Pfizer also announced FDA approval for Talzenna in combination with Xtandi for metastatic hormone-sensitive prostate cancer with HRR gene mutations. PFE stock is down slightly in pre-market trading.

The FDA expanded Pfizer's Talzenna-Xtandi approval for earlier prostate cancer treatment. Based on the TALAPRO-3 study, the combo reduced progression/death risk by 52%. It now treats metastatic hormone-sensitive prostate cancer with HRR gene mutations. Pfizer aims to address unmet needs in this patient population.

Pfizer (PFE) reported that its Phase 3 study of ELREXFIO (elranatamab) met its primary endpoint, showing a significant reduction in disease progression or death in relapsed or refractory multiple myeloma patients. The study involved 523 adults across 26 countries. Pfizer plans to submit the data to global health authorities. ELREXFIO is already approved in over 35 countries for similar indications.

Pfizer reported that its Phase 3 MagnetisMM-32 trial for ELREXFIO met its primary endpoint, showing a 68% progression-free survival rate at 18 months. The company plans regulatory filings, though overall survival data is not yet mature. According to Pfizer, the results support ELREXFIO's potential use in earlier relapsed/refractory multiple myeloma settings.

Pfizer's Phase 3 MagnetisMM-32 trial of ELREXFIO (elranatamab) met its primary endpoint, showing a statistically significant reduction in disease progression or death for multiple myeloma patients. Over 75% of patients showed no progression or death at analysis. Pfizer plans to submit these data to global health authorities. ELREXFIO demonstrated a favorable safety profile, with no new safety signals identified.

Pfizer (PFE) announced FDA expanded approval of Talzenna (talazoparib) with Xtandi (enzalutamide) for metastatic prostate cancer with HRR gene mutations. The approval is based on TALAPRO-3 trial data showing a 52% reduction in progression or death risk. The combination is now approved for earlier-stage treatment, with a known safety profile.